BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The company has developed a differentiated technology platform that combines cutting-edge Artificial Intelligence (AI) and science to drive a revolution in drug discovery.

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

BAI

COM:BENEVOLENT

BenevolentAI

Last Close

0.73

22/11 16:35

Volume Today

4.65K

Avg: -

market

industry

website

crunchbase

peer of

investor of

competitor of

Metrics